Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Operating Margin (2021 - 2025)

Aligos Therapeutics' Operating Margin history spans 5 years, with the latest figure at 36186.98% for Q4 2025.

  • For Q4 2025, Operating Margin rose 3681010.0% year-over-year to 36186.98%; the TTM value through Dec 2025 reached 229.41%, up 118461.0%, while the annual FY2025 figure was 229.41%, 223954.0% up from the prior year.
  • Operating Margin reached 36186.98% in Q4 2025 per ALGS's latest filing, up from 3827.4% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 36186.98% in Q4 2025 to a low of 17084.29% in Q1 2023.
  • Average Operating Margin over 5 years is 1242.26%, with a median of 1918.82% recorded in 2021.
  • Peak YoY movement for Operating Margin: tumbled -1570128bps in 2023, then skyrocketed 3681010bps in 2025.
  • A 5-year view of Operating Margin shows it stood at 10340.05% in 2021, then surged by 98bps to 163.1% in 2022, then tumbled by -693bps to 1294.03% in 2023, then surged by 52bps to 623.12% in 2024, then skyrocketed by 5907bps to 36186.98% in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Operating Margin are 36186.98% (Q4 2025), 3827.4% (Q3 2025), and 1924.04% (Q2 2025).